WO2017206948A1 - 新型二氮杂二环β-内酰胺酶抑制剂 - Google Patents

新型二氮杂二环β-内酰胺酶抑制剂 Download PDF

Info

Publication number
WO2017206948A1
WO2017206948A1 PCT/CN2017/087004 CN2017087004W WO2017206948A1 WO 2017206948 A1 WO2017206948 A1 WO 2017206948A1 CN 2017087004 W CN2017087004 W CN 2017087004W WO 2017206948 A1 WO2017206948 A1 WO 2017206948A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
acid
group
mmol
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2017/087004
Other languages
English (en)
French (fr)
Inventor
胡伯羽
丁照中
黄志刚
来巍
林锐彬
肖敏亮
雷鸽娟
谢金生
胡国平
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medshine Discovery Inc
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of WO2017206948A1 publication Critical patent/WO2017206948A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Definitions

  • the present invention relates to a series of novel diazabicyclo ⁇ -lactamase inhibitors, in particular to a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • Beta-lactam antibiotics have been used for more than 70 years and are the main varieties of clinical treatment of various infections.
  • bacterial resistance is also rapidly increasing.
  • the situation facing physicians has become worse and worse, that is, the incidence and mortality of bacterial infections are rising rapidly in both communities and hospitals.
  • MDR multidrug-resistant strains
  • XDR extremely drug-resistant strains
  • ESKAPE includes Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and intestines. 6 pathogenic bacteria such as Enterobacterspecies. These six strains cover most MDR and XDR strains, greatly limiting the choice of treatment options for physicians.
  • bacteria can be resistant to ⁇ -lactam antibiotics. The most important thing is that bacteria can produce enzymes that hydrolyze the ⁇ -lactam ring, causing antibiotics to lose their antibacterial activity. Bacteria can also selectively alter the target of antibiotic action. For example, multi-drug resistance of methicillin-resistant Staphylococcus aureus is associated with the production of new PBP 2a , increased synthesis of PBPs, and decreased drug affinity. The ⁇ -lactamase can rapidly bind to certain enzyme-resistant ⁇ -lactam antibiotics, allowing the drug to stay in the extracellular space of the cytoplasm, failing to reach the target site to exert an antibacterial effect.
  • the outer membrane of G-bacteria is not easily permeable to certain ⁇ -lactam antibiotics, resulting in non-specific low-level resistance.
  • Bacteria can produce various types of ⁇ -lactamases, which can be classified into four categories A, B, C, and D according to their amino acid and nucleotide sequences. Class A, B, and D enzymes catalyze hydrolysis with serine as the active site, and class B enzymes cleave the ring by one or more metal atoms at its active site.
  • the first well-known high-activity beta-lactamase inhibitor is potassium clavulanate, and its combination with amoxicillin has so far been popular in the market.
  • Two other important beta-lactamase inhibitors on the market are sulbactam and tazobactam. What these three drugs have in common is that the structure has a highly active ⁇ -lactam ring, which is the active site of the inhibitor. Although the three drugs are hot in the market, their antibacterial spectrum is very narrow. They have only an effect on the A- and D-class ⁇ -lactamases, but are completely ineffective against the K-type enzymes of the C-type enzymes and the A-class.
  • the drug contains a novel diazabicyclo ring structure that has a broader spectrum of antibacterial activity than the three older generation beta-lactamase inhibitors described above.
  • a large number of new compounds of the diazabicyclo ring are disclosed in the patents of the ⁇ -lactamase inhibitors, including: WO2009133442, WO2009091856, WO2010126820, WO2012086241, WO2013030733, WO2013030735, WO2013149121, WO2013149136, WO2013180197, WO20140191268, WO2014141132, WO2014135931, WO2015063653 , WO2015110885, US20140296526.
  • two new drugs, MK-7655 and OP-0595 have entered the clinical stage.
  • MK-7655 has entered phase III clinical trial
  • OP-0595 has entered phase I clinical.
  • OP-0595 is extremely active in vitro and is owned by Roche Pharmaceuticals. Wockhardt, Inc. of India is also conducting research on diazonium heterocyclic inhibitors, in which the compound REF-1 is disclosed in the company's two patents US20150203503A1 and WO2014033560A1, which have certain biological activity. Therefore, diazabicyclic inhibitors will be a new direction in the development of ⁇ -lactamase inhibitors.
  • the present invention provides a compound of the formula (I) or a pharmaceutically acceptable salt thereof,
  • n 1 or 2;
  • n 1 or 2;
  • i 1, 2 or 3.
  • the above compound, or a pharmaceutically acceptable salt thereof is selected from
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of a compound according to the above claims, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • the present invention also provides the use of the above compound or a pharmaceutically acceptable salt thereof or the above pharmaceutical composition for the preparation of a ⁇ -lactamase inhibitor for treating a bacterial infection.
  • a base addition salt refers to a salt of a compound of the invention, a compound having a particular substituent found by the present invention and relatively free Preparation of toxic acids or bases.
  • a base addition salt can be obtained by contacting a neutral amount of such a compound with a sufficient amount of a base in a neat solution or a suitable inert solvent.
  • Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic ammonia or magnesium salts or similar salts.
  • an acid addition salt can be obtained by contacting a neutral form of such a compound with a sufficient amount of an acid in a neat solution or a suitable inert solvent.
  • pharmaceutically acceptable acid addition salts include inorganic acid salts including, for example, hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, hydrogencarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, Hydrogen sulfate, hydroiodic acid, phosphorous acid, etc.; and an organic acid salt, such as acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, Similar acids such as fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid, and me
  • the salt is contacted with a base or acid in a conventional manner, and the parent compound is separated, thereby regenerating the neutral form of the compound.
  • the parent form of the compound differs from the form of its various salts by certain physical properties, such as differences in solubility in polar solvents.
  • a "pharmaceutically acceptable salt” is a derivative of a compound of the invention wherein the parent compound is modified by salt formation with an acid or with a base.
  • pharmaceutically acceptable salts include, but are not limited to, inorganic or organic acid salts of bases such as amines, alkali metal or organic salts of acid groups such as carboxylic acids, and the like.
  • Pharmaceutically acceptable salts include the conventional non-toxic salts or quaternary ammonium salts of the parent compound, for example salts formed from non-toxic inorganic or organic acids.
  • non-toxic salts include, but are not limited to, those derived from inorganic acids and organic acids selected from the group consisting of 2-acetoxybenzoic acid, 2-hydroxyethanesulfonic acid, acetic acid, ascorbic acid, Benzenesulfonic acid, benzoic acid, hydrogencarbonate, carbonic acid, citric acid, edetic acid, ethane disulfonic acid, ethanesulfonic acid, fumaric acid, glucoheptose, gluconic acid, glutamic acid, glycolic acid, Hydrobromic acid, hydrochloric acid, hydroiodide, hydroxyl, hydroxynaphthalene, isethionethane, lactic acid, lactose, dodecylsulfonic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, nitric acid, oxalic acid, Pamoic acid, pantothenic acid, phenylacetic acid, phen
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound containing an acid group or a base by conventional chemical methods.
  • such salts are prepared by reacting these compounds in water or an organic solvent or a mixture of the two via a free acid or base form with a stoichiometric amount of a suitable base or acid.
  • a nonaqueous medium such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile is preferred.
  • the compounds provided herein also exist in the form of prodrugs.
  • Prodrugs of the compounds described herein are readily chemically altered under physiological conditions to convert to the compounds of the invention.
  • prodrugs can be converted to the compounds of the invention by chemical or biochemical methods in an in vivo setting.
  • Certain compounds of the invention may exist in unsolvated or solvated forms, including hydrated forms.
  • the solvated forms are equivalent to the unsolvated forms and are included within the scope of the invention.
  • Certain compounds of the invention may have asymmetric carbon atoms (optical centers) or double bonds. Racemates, diastereomers, geometric isomers and individual isomers are included within the scope of the invention.
  • the compounds of the invention may exist in specific geometric or stereoisomeric forms.
  • the present invention contemplates all such compounds, including the cis and trans isomers, the (-)- and (+)-p-enantiomers, the (R)- and (S)-enantiomers, and the diastereomeric a conformation, a (D)-isomer, a (L)-isomer, and a racemic mixture thereof, and other mixtures, such as enantiomerically or diastereomeric enriched mixtures, all of which belong to It is within the scope of the invention.
  • Additional asymmetric carbon atoms may be present in the substituents such as alkyl groups. All such isomers, as well as mixtures thereof, are included within the scope of the invention.
  • optically active (R)- and (S)-isomers as well as the D and L isomers can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If an enantiomer of a compound of the invention is desired, it can be prepared by asymmetric synthesis or by derivatization with a chiral auxiliary wherein the resulting mixture of diastereomers is separated and the auxiliary group cleaved to provide pure The desired enantiomer.
  • a diastereomeric salt is formed with a suitable optically active acid or base, followed by conventional methods well known in the art.
  • the diastereomers are resolved and the pure enantiomer is recovered.
  • the separation of enantiomers and diastereomers is generally accomplished by the use of chromatography using a chiral stationary phase, optionally in combination with chemical derivatization (eg, formation of an amino group from an amine). Formate).
  • the compounds of the present invention may contain unnatural proportions of atomic isotopes on one or more of the atoms that make up the compound.
  • radiolabeled compounds can be used, such as tritium (3 H), iodine -125 (125 I) or C-14 (14 C). Alterations of all isotopic compositions of the compounds of the invention, whether radioactive or not, are included within the scope of the invention.
  • pharmaceutically acceptable carrier refers to any formulation or carrier medium that is capable of delivering an effective amount of an active substance of the present invention, does not interfere with the biological activity of the active substance, and has no toxic side effects to the host or patient, including water, oil, Vegetables and minerals, cream bases, lotion bases, ointment bases, etc. These bases include suspending agents, tackifiers, transdermal enhancers and the like. Their formulations are well known to those skilled in the cosmetic or topical pharmaceutical arts. For additional information on vectors, reference is made to Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott, Williams & Wilkins (2005), the contents of which are hereby incorporated by reference.
  • excipient generally refers to the carrier, diluent and/or vehicle required to formulate an effective pharmaceutical composition.
  • an "effective amount” or “therapeutically effective amount” with respect to a pharmaceutical or pharmacologically active agent refers to a sufficient amount of a drug or agent that is non-toxic but that achieves the desired effect.
  • an "effective amount” of an active substance in a composition refers to the amount required to achieve the desired effect when used in combination with another active substance in the composition. The determination of the effective amount will vary from person to person, depending on the age and general condition of the recipient, and also on the particular active substance, and a suitable effective amount in a case can be determined by one skilled in the art based on routine experimentation.
  • active ingredient refers to a chemical entity that is effective in treating a target disorder, disease or condition.
  • substituted means that any one or more hydrogen atoms on a particular atom are replaced by a substituent, and may include variants of heavy hydrogen and hydrogen, as long as the valence of the particular atom is normal and the substituted compound is stable. of.
  • Ketone substitution does not occur on the aryl group.
  • optionally substituted means that it may or may not be substituted, and unless otherwise specified, the kind and number of substituents may be arbitrary on the basis of chemically achievable.
  • any variable eg, R
  • its definition in each case is independent.
  • the group may optionally be substituted at most by two R, and each In this case, R has separate options.
  • substituents and/or variants thereof are permissible only if such combinations result in stable compounds.
  • linking group When the number of one linking group is 0, such as -(CRR) 0 -, it indicates that the linking group is a single bond.
  • one of the variables When one of the variables is selected from a single bond, it means that the two groups to which it is attached are directly linked. For example, when L represents a single bond in A-L-Z, the structure is actually A-Z.
  • substituent When a substituent is vacant, it means that the substituent is absent. For example, when X is vacant in AX, the structure is actually A. When a bond of a substituent can be cross-linked to two atoms on a ring, the substituent can be bonded to any atom on the ring. When the recited substituents do not indicate which atom is attached to a compound included in the chemical structural formula including but not specifically mentioned, such a substituent may be bonded through any atomic phase thereof. Combinations of substituents and/or variants thereof are permissible only if such combinations result in stable compounds. For example, a structural unit It is indicated that it can be substituted at any position on the cyclohexyl or cyclohexadiene.
  • hetero denotes a hetero atom or a hetero atomic group (ie, a radical containing a hetero atom), including atoms other than carbon (C) and hydrogen (H), and radicals containing such heteroatoms, including, for example, oxygen (O).
  • ring means substituted or unsubstituted cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, cycloalkynyl, heterocycloalkynyl, aryl or heteroaryl. So-called rings include single rings, interlocking rings, spiral rings, parallel rings or bridge rings. The number of atoms on the ring is usually defined as the number of elements of the ring. For example, "5 to 7-membered ring” means 5 to 7 atoms arranged in a circle. Unless otherwise specified, the ring optionally contains from 1 to 3 heteroatoms.
  • 5- to 7-membered ring includes, for example, phenyl, pyridine, and piperidinyl; on the other hand, the term “5- to 7-membered heterocycloalkyl ring” includes pyridyl and piperidinyl, but does not include phenyl.
  • ring also includes ring systems containing at least one ring, each of which "ring” independently conforms to the above definition.
  • heterocycle or “heterocyclyl” means a stable monocyclic, bicyclic or tricyclic ring containing a hetero atom or a heteroatom group which may be saturated, partially unsaturated or unsaturated ( Aromatic) which comprise a carbon atom and 1, 2, 3 or 4 ring heteroatoms independently selected from N, O and S, wherein any of the above heterocycles may be fused to a phenyl ring to form a bicyclic ring.
  • the nitrogen and sulfur heteroatoms can be optionally oxidized (i.e., NO and S(O)p, p is 1 or 2).
  • the nitrogen atom can be substituted or unsubstituted (i.e., N or NR, wherein R is H or other substituents as already defined herein).
  • the heterocyclic ring can be attached to the side groups of any hetero atom or carbon atom to form a stable structure. If the resulting compound is stable, the heterocycles described herein can undergo substitutions at the carbon or nitrogen sites.
  • the nitrogen atom in the heterocycle is optionally quaternized.
  • a preferred embodiment is that when the total number of S and O atoms in the heterocycle exceeds 1, these heteroatoms are not adjacent to each other. Another preferred embodiment is that the total number of S and O atoms in the heterocycle does not exceed one.
  • aromatic heterocyclic group or "heteroaryl” as used herein means a stable 5, 6, or 7 membered monocyclic or bicyclic or aromatic ring of a 7, 8, 9 or 10 membered bicyclic heterocyclic group, It contains carbon atoms and 1, 2, 3 or 4 ring heteroatoms independently selected from N, O and S.
  • the nitrogen atom can be substituted or unsubstituted (i.e., N or NR, wherein R is H or other substituents as already defined herein).
  • the nitrogen and sulfur heteroatoms can be optionally oxidized (i.e., NO and S(O)p, p is 1 or 2).
  • bridged rings are also included in the definition of heterocycles.
  • a bridged ring is formed when one or more atoms (ie, C, O, N, or S) join two non-adjacent carbon or nitrogen atoms.
  • Preferred bridged rings include, but are not limited to, one carbon atom, two carbon atoms, one nitrogen atom, two nitrogen atoms, and one carbon-nitrogen group. It is worth noting that a bridge always converts a single ring into a three ring. In the bridged ring, a substituent on the ring can also be present on the bridge.
  • heterocyclic compounds include, but are not limited to, acridinyl, octanoyl, benzimidazolyl, benzofuranyl, benzofuranylfuranyl, benzindenylphenyl, benzoxazolyl, benzimidin Oxazolinyl, benzothiazolyl, benzotriazolyl, benzotetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolyl, oxazolyl, 4aH-carbazolyl, Porphyrin, chroman, chromene, porphyrin-decahydroquinolinyl, 2H, 6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b] Tetrahydrofuranyl, furyl, furfuryl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-carbazolyl, nonenyl,
  • hydrocarbyl or its subordinate concept (such as alkyl, alkenyl, alkynyl, aryl, etc.), by itself or as part of another substituent, is meant to be straight-chain, branched or cyclic.
  • the hydrocarbon atom group or a combination thereof may be fully saturated (such as an alkyl group), a unit or a polyunsaturated (such as an alkenyl group, an alkynyl group, an aryl group), may be monosubstituted or polysubstituted, and may be monovalent (such as Methyl), divalent (such as methylene) or polyvalent (such as methine), may include divalent or polyvalent radicals with a specified number of carbon atoms (eg, C 1 -C 12 represents 1 to 12 carbons) , C 1-12 is selected from C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , C 10 , C 11 and C 12 ; C 3-12 is selected from C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , C 10 , C 11 and C 12 .).
  • C 1-12 is selected from C 1
  • Hydrocarbyl includes, but is not limited to, aliphatic hydrocarbyl groups including chain and cyclic, including but not limited to alkyl, alkenyl, alkynyl groups including, but not limited to, 6-12 members.
  • An aromatic hydrocarbon group such as benzene, naphthalene or the like.
  • hydrocarbyl means a straight or branched chain radical or a combination thereof, which may be fully saturated, unitary or polyunsaturated, and may include divalent and multivalent radicals.
  • saturated hydrocarbon radicals include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, isobutyl, cyclohexyl, (cyclohexyl).
  • a homolog or isomer of a methyl group, a cyclopropylmethyl group, and an atomic group such as n-pentyl, n-hexyl, n-heptyl, n-octyl.
  • the unsaturated hydrocarbon group has one or more double or triple bonds, and examples thereof include, but are not limited to, a vinyl group, a 2-propenyl group, a butenyl group, a crotyl group, a 2-isopentenyl group, and a 2-(butadienyl group). , 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and higher homologs and isomers body.
  • heterohydrocarbyl or its subordinate concept (such as heteroalkyl, heteroalkenyl, heteroalkynyl, heteroaryl, etc.), by itself or in combination with another term, means a stable straight chain, branched chain. Or a cyclic hydrocarbon radical or a combination thereof having a number of carbon atoms and at least one heteroatom.
  • heteroalkyl by itself or in conjunction with another term refers to a stable straight chain, branched hydrocarbon radical or combination thereof, having a number of carbon atoms and at least one heteroatom.
  • the heteroatoms are selected from the group consisting of B, O, N, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen heteroatoms are optionally quaternized.
  • the hetero atom or heteroatom group may be located at any internal position of the heterohydrocarbyl group, including where the hydrocarbyl group is attached to the rest of the molecule, but the terms "alkoxy”, “alkylamino” and “alkylthio” (or thioalkoxy). By customary expression, those alkyl groups which are attached to the remainder of the molecule through an oxygen atom, an amino group or a sulfur atom, respectively.
  • Up to two heteroatoms may be consecutive, for example, -CH 2 -NH-OCH 3.
  • cycloalkyl refers to any heterocyclic alkynyl group, etc., by itself or in combination with other terms, denotes a cyclized “hydrocarbyl group” or “heterohydrocarbyl group”, respectively.
  • a hetero atom may occupy a position at which the hetero ring is attached to the rest of the molecule.
  • cycloalkyl groups include, but are not limited to, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like.
  • heterocyclic groups include 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothiophen-2-yl, tetrahydrothiophen-3-yl, 1-piperazinyl and 2-piperazinyl.
  • alkyl is used to denote a straight or branched saturated hydrocarbon group, which may be monosubstituted (eg, -CH 2 F) or polysubstituted (eg, -CF 3 ), and may be monovalent (eg, Methyl), divalent (such as methylene) or polyvalent (such as methine).
  • alkyl group include methyl (Me), ethyl (Et), propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, s-butyl). , t-butyl), pentyl (eg, n-pentyl, isopentyl, neopentyl) and the like.
  • alkenyl refers to an alkyl group having one or more carbon-carbon double bonds at any position of the chain, which may be mono- or poly-substituted, and may be monovalent, divalent or multivalent.
  • alkenyl group include a vinyl group, a propenyl group, a butenyl group, a pentenyl group, a hexenyl group, a butadienyl group, a pentadienyl group, a hexadienyl group and the like.
  • alkynyl refers to an alkyl group having one or more carbon-carbon triple bonds at any position of the chain, which may be mono- or poly-substituted, and may be monovalent, divalent or multivalent.
  • alkynyl groups include ethynyl, propynyl, butynyl, pentynyl and the like.
  • a cycloalkyl group includes any stable cyclic or polycyclic hydrocarbon group, any carbon atom which is saturated, may be monosubstituted or polysubstituted, and may be monovalent, divalent or multivalent.
  • Examples of such cycloalkyl groups include, but are not limited to, cyclopropyl, norbornyl, [2.2.2]bicyclooctane, [4.4.0]bicyclononane, and the like.
  • a cycloalkenyl group includes any stable cyclic or polycyclic hydrocarbon group which contains one or more unsaturated carbon-carbon double bonds at any position of the ring, and may be monosubstituted or polysubstituted, It can be one price, two price or multiple price.
  • Examples of such cycloalkenyl groups include, but are not limited to, cyclopentenyl, cyclohexenyl, and the like.
  • a cycloalkynyl group includes any stable cyclic or polycyclic hydrocarbon group which contains one or more carbon-carbon triple bonds at any position of the ring, which may be monosubstituted or polysubstituted, and may be one Price, price or price.
  • halo or “halogen”, by itself or as part of another substituent, denotes a fluorine, chlorine, bromine or iodine atom.
  • haloalkyl is intended to include both monohaloalkyl and polyhaloalkyl.
  • halo(C 1 -C 4 )alkyl is intended to include, but is not limited to, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like. Wait.
  • examples of haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl.
  • alkoxy represents attached through an oxygen bridge
  • C 1-6 alkoxy groups include C 1, C 2, C 3 , C 4, C 5 , and C 6 alkoxy groups.
  • alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentyloxy and S- Pentyloxy.
  • aryl denotes a polyunsaturated, aromatic hydrocarbon substituent which may be monosubstituted or polysubstituted, which may be monovalent, divalent or polyvalent, which may be monocyclic or polycyclic ( For example, 1 to 3 rings; at least one of which is aromatic), they are fused together or covalently linked.
  • heteroaryl refers to an aryl (or ring) containing one to four heteroatoms. In an illustrative example, the heteroatoms are selected from the group consisting of B, N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom is optionally quaternized.
  • a heteroaryl group can be attached to the remainder of the molecule through a heteroatom.
  • aryl or heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyridyl Azyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxan Azyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thiophene , 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-benzothiazolyl, 5-
  • aryl groups when used in conjunction with other terms (e.g., aryloxy, arylthio, aralkyl), include aryl and heteroaryl rings as defined above.
  • aralkyl is intended to include those radicals to which an aryl group is attached to an alkyl group (eg, benzyl, phenethyl, pyridylmethyl, and the like), including wherein the carbon atom (eg, methylene) has been, for example, oxygen.
  • alkyl groups substituted by an atom such as phenoxymethyl, 2-pyridyloxymethyl 3-(1-naphthyloxy)propyl and the like.
  • leaving group refers to a functional group or atom which may be substituted by another functional group or atom by a substitution reaction (for example, an affinity substitution reaction).
  • substituent groups include triflate; chlorine, bromine, iodine; sulfonate groups such as mesylate, tosylate, p-bromobenzenesulfonate, p-toluenesulfonic acid Esters and the like; acyloxy groups such as acetoxy, trifluoroacetoxy and the like.
  • protecting group includes, but is not limited to, "amino protecting group", “hydroxy protecting group” or “thiol protecting group”.
  • amino protecting group refers to a protecting group suitable for preventing side reactions at the amino nitrogen position.
  • Representative amino protecting groups include, but are not limited to, formyl; acyl, such as alkanoyl (e.g., acetyl, trichloroacetyl or trifluoroacetyl); alkoxycarbonyl, e.g., tert-butoxycarbonyl (Boc) Arylmethoxycarbonyl, such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethoxycarbonyl (Fmoc); arylmethyl, such as benzyl (Bn), trityl (Tr), 1, 1-di -(4'-methoxyphenyl)methyl; silyl groups such as trimethylsilyl (TMS) and tert-
  • hydroxy protecting group refers to a protecting group suitable for use in preventing hydroxy side reactions.
  • Representative hydroxy protecting groups include, but are not limited to, alkyl groups such as methyl, ethyl and t-butyl groups; acyl groups such as alkanoyl groups (e.g., acetyl); arylmethyl groups such as benzyl (Bn), Oxybenzyl (PMB), 9-fluorenylmethyl (Fm) and diphenylmethyl (diphenylmethyl, DPM); silyl groups such as trimethylsilyl (TMS) and tert-butyl Dimethylsilyl (TBS) and the like.
  • alkyl groups such as methyl, ethyl and t-butyl groups
  • acyl groups such as alkanoyl groups (e.g., acetyl)
  • arylmethyl groups such as benzyl (Bn), Oxybenzyl (PMB), 9-fluoreny
  • the compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments set forth below, combinations thereof with other chemical synthetic methods, and those well known to those skilled in the art. Equivalent alternatives, preferred embodiments include, but are not limited to, embodiments of the invention.
  • the solvent used in the present invention is commercially available.
  • the present invention employs the following abbreviations: aq for water; HATU for O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate ; EDC stands for N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride; m-CPBA stands for 3-chloroperoxybenzoic acid; eq stands for equivalent, equivalent; CDI stands for Carbonyldiimidazole; DCM stands for dichloromethane; PE stands for petroleum ether; DIAD stands for diisopropyl azodicarboxylate; DMF stands for N,N-dimethylformamide; DMSO stands for dimethyl sulfoxide; EtOAc stands for acetic acid Esters; EtOH for ethanol; MeOH for methanol; CBz for benzyl
  • Figure 1 is a comparison of the efficacy of Compound 1 and the reference compound OP-0595 in a mouse thigh muscle infection model.
  • Figure 2 is a comparison of the dose-effect relationship between the compound 1-H2 and the reference compound OP-0595 in a mouse thigh muscle infection model.
  • step 1
  • step 1
  • the activated zinc powder (12.41 g, 189.87 mmol) was suspended in 150 ml of tetrahydrofuran, trimethylchlorosilane (317.31 mg, 2.92 mmol, 0.369 ml) was added at 35 ° C, and then slowly cooled at 66 ° C under nitrogen atmosphere. Ethyl bromoacetate (9.27 g, 55.5 mmol, 6.14 ml) was added dropwise. During the reaction, the suspension gradually turned into a clear orange solution. After the zinc powder was completely dissolved, it was cooled to 20 ° C and transferred to a dropping funnel.
  • reaction was quenched with 10 mL of saturated sodium hydrogen sulfate and the pH of the reaction mixture was adjusted to about 5, then ethyl acetate / petroleum ether (1:1)
  • the mixed solution was washed twice with 15 ml each time, and tetrabutylammonium hydrogen sulfate (271.33 mg, 0.8 mmol) was added to the aqueous phase and stirred at 15 ° C for 10 minutes, then extracted twice with ethyl acetate.
  • the organic phase was combined and washed once with 10 ml of brine, dried over anhydrous sodium sulfate and filtered to afford compound 4-H (260 mg, yield 90%).
  • step 1
  • reaction temperature was slowly raised to 20 ° C, stirred for 1 hour, thin layer chromatography analysis showed that the raw material 7-B consumption was complete, at this time the reaction was re-cooled to 0 ° C, slowly added 3 mol / liter of sodium hydroxide solution 9.38 ml, tight Then, hydrogen peroxide (3.19 g, 28.14 mmol, 30%) was added, then the reaction temperature was raised to 20 ° C and stirred for 2 hours. The thin layer chromatography showed that the reaction intermediate was consumed completely, and the reaction solution was poured into 10 ml of water with ethyl acetate.
  • the synergistic inhibition concentration test was established based on the Clinical Laboratory Standardization Association (CLSI) method M7, with a combined initial concentration of antibiotics of 128 ⁇ g/ml for continuous dilution, for a total of 11 serial dilutions, active ⁇ -lactam
  • CLSI Clinical Laboratory Standardization Association
  • the enzyme inhibitor test concentration was fixed at 4 ⁇ g/ml.
  • test compound is dissolved (if it is not dissolved, it can be suspended) diluted in dimethyl sulfoxide to a concentration of 12.8 mg/ml as a stock solution, and ceftazidime (CAZ) is dissolved in water and diluted to 25.6 mg/ml, erectem ( ETP) was diluted in phosphate buffered saline (PBS) to 25.6 mg/ml.
  • CAZ ceftazidime
  • ETP erectem
  • PBS phosphate buffered saline
  • test compound After diluting the test compound at a concentration of 12.8 mg/ml with DMSO to 0.8 mg/ml, 30 ⁇ L was added to one column of the mother plate. Mix the liquid in the mother board with a lance.
  • 96-U type plate as a test plate.
  • the experimental plate was incubated at 37 ° C for 20 hours.
  • the minimum inhibitory concentration of ceftazidime is the lowest concentration that can completely or significantly inhibit bacterial growth.
  • Table 1 is the specific information of the ⁇ -lactamase-producing bacterial strain used in the experiment:
  • the compound 1-H2 also showed antibacterial activity against Enterobacter cloacae, and the inhibitory concentration was below 8 ⁇ g/ml, which was equivalent to OP-0595. Therefore, the isomer 1-H2 after compound 1 resolution is superior to the reference compound OP-0595.
  • the in vitro activity of Compound 4 was also slightly better than that of reference compound OP-0595.
  • This test was designed to evaluate the advantages of the compounds in the examples compared to the inhibitory activity of OP-0595 on ⁇ -lactamase.
  • the microplate reader can give a curve of OD490 growth over time.
  • the slopes of the curves (Abs2-Abs1)/(T2-T1) were calculated by taking two data points Abs1 and Abs2 within the linear range of the curve.
  • Slope (EC) is the slope in the absence of inhibitor and Slop (S) is the slope at a certain inhibitor concentration.
  • PBS refers to phosphate buffer solution
  • BSA bovine serum albumin
  • mice Female CD-1 mice of about 7 weeks old, weighing 26-28 grams; 150 mg/kg 4 days before cyclophosphamide infection, 100 mg/kg 1 day before; the infected bacteria is Enterobacter cloacae 1143 ( AmpC).
  • Compound 1,1-H2, reference compound OP-0595 All have laboratory synthesis.
  • Each female CD-1 mouse was infected with Klebsiella pneumoniae by injecting 100 microliters of bacterial solution into the right leg muscle.
  • the infection dose was greater than 5.00E+05 CFU per mouse, and 2 hours after infection, each group of mice passed the tail vein.
  • the corresponding compound or combination of compounds is administered, and after the first treatment interval of 8 hours, a second round of treatment is given.
  • mice were euthanized 24 hours after infection, and the right leg thigh muscles were placed in a 50 ml centrifuge tube containing 10 ml of sterile physiological saline, placed on wet ice and transferred to a BSL-2 laboratory for CFU counting.
  • the muscle tissue was ground using an IKA T10 homogenizer (maximum rotation speed 20S, repeated once).
  • the homogenate was diluted in a gradient and placed on a tryptone soy agar plate.
  • the bacteria were cultured in a 37 ° C incubator. After 24 hours, the plate was removed and the plate was counted. The number of single colonies grown on each of the diluted gradient homogenates was calculated, and the amount of bacteria in the leg muscles of each mouse was calculated therefrom.
  • the compound 1 group was reduced by 0.59 log more than the reference compound OP-0595, and its efficacy was improved by 3.9 times.
  • Compound 1 was significantly more potent than the reference compound OP-0595.
  • Compound 1-H2 showed superior efficacy against the reference compound OP-0595 at different doses in the model.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了一系列新型二氮杂二环β-内酰胺酶抑制剂，具体公开了式(I)所示化合物或其药学上可接受的盐。

Description

新型二氮杂二环β-内酰胺酶抑制剂 发明领域
本发明涉及一系列新型二氮杂二环β-内酰胺酶抑制剂，具体公开了式(Ⅰ)所示化合物或其药学上可接受的盐。
发明背景
β-内酰胺类抗生素使用至今已有70多年，是临床上治疗各种感染的主力品种。但是，随着这类药物的大量使用和滥用，细菌耐药性也在快速增加。过去的20年间，内科医生面临的境况越来越糟，那就是无论是在社区还是医院，细菌性感染的发病率和死亡率都在迅速攀升。临床上耐受抗生素能力强且亟需新治疗药物的致病菌株主要有两种：一种是多重耐药菌(multidrug-resistant strains，MDR)，是指细菌对常用抗菌药物主要分类的3类或以上耐药；另一种是广泛耐药菌(extremely drug-resistant strains，XDR)，是指细菌对常用抗菌药物几乎全部耐药。院内感染的30-50％是ESKAPE导致的。ESKAPE包括屎肠球菌(Enterococcus faecium)、金黄色葡萄球菌(Staphylococcus aureus)、肺炎克雷伯菌(Klebsiella pneumoniae)、鲍氏不动杆菌(Acinetobacter baumannii)、铜绿假单胞菌(Pseudomonas aeruginosa)及肠杆菌属(Enterobacterspecies)等6类致病菌。这六类菌涵盖了大多数的MDR和XDR菌株，极大地限制了医生对于治疗方案的选择。
细菌对β-内酰胺类抗生素产生耐药的机制有几种，最主要的是细菌能产生使β-内酰胺环水解开裂的酶，从而导致抗生素失去抗菌活性。细菌还可以选择性改变抗生素的作用靶标。如耐甲氧西林金黄色葡萄球菌具有多重耐药性就与产生新的PBP2a、使PBPs合成增加、与药物亲和力下降有关。β-内酰胺酶可与某些耐酶β-内酰胺类抗生素迅速结合，使药物停留在胞质膜外间隙中，不能达到作用靶位发挥抗菌作用。另外，G-菌的外膜对某些β-内酰胺类抗生素不易透过，产生非特异性低水平耐药。还有些细菌的胞质膜上存在主动外排系统，细菌由此主动外排药物。因此，将β-内酰胺类抗生素和β-内酰胺酶抑制剂联合使用是临床上最有效的方法。细菌可以产生多种类型的β-内酰胺酶，按照其氨基酸和核苷酸序列可以分为A、B、C、D四类。A、B和D类酶以丝氨酸为活性位点来催化水解，B类酶通过其活性位点上的一个或多个金属原子使环开裂。
Figure PCTCN2017087004-appb-000001
第一个广为人知的高活性β-内酰胺酶抑制剂是克拉维酸钾，迄今为止，它与阿莫西林的组合在市场上仍然畅销。市场上另外两个重要的β-内酰胺酶抑制剂是舒巴坦和他唑巴坦。这三个药物的共同之处是结构中都有高活性的β-内酰胺环，是抑制剂的活性位点。虽然这三个药物在市场销售情况火热，但是其本身的抗菌谱很窄。它们只对A和D类β-内酰胺酶有作用效果，而对C类酶和A类中极为重要的KPC酶则完全无效。
2015年2月，FDA批准了一种新的β-内酰胺酶抑制剂，名叫阿维巴坦(NXL-104)。该药物的结构中含有一个新型的二氮杂二环，具有比上述三个老一代的β-内酰胺酶抑制剂更广的抗菌谱。β-内酰胺酶抑制剂的专利中披露了大量的二氮杂二环的新化合物，包括：WO2009133442,WO2009091856,WO2010126820,WO2012086241,WO2013030733,WO2013030735,WO2013149121,WO2013149136,WO2013180197,WO20140191268,WO2014141132,WO2014135931,WO2015063653,WO2015110885,US20140296526。其中，MK-7655和OP-0595这两个新药已进入临床阶段。MK-7655已进入III期临床，OP-0595已进入I期临床。OP-0595体外活性极好，为罗氏制药所有。印度的Wockhardt公司也在进行二氮杂环类抑制剂研究，其中化合物REF-1在该公司两篇专利US20150203503A1和WO2014033560A1中被公开，具有一定的生物活性。因此，二氮杂二环类抑制剂将会是β-内酰胺酶抑制剂开发的一个新的方向。
Figure PCTCN2017087004-appb-000002
目前，抗生素耐药已经成为一个世界性的卫生问题，世界范围内新的耐药菌不断出现。伴随当下抗生素研发步伐放缓,临床上面临的抗菌治疗日趋严峻,甚至出现"无药可用"的情况.鉴于此种情况，开发新的安全、高效的β-内酰胺酶抑制剂是刻不容缓、势在必行的。
背景研发资料参考以下文献：
[1]US2013225554A1；
[2]WO2014091268A1；
[3]WO2014033560A1；
[4]S.Biondi,S.Long,M.Panunzio and W.L.Qin,Curr.Med.Chem.,2011(18),4223-4236；
[5]Ken Garber,Nat.Rev.Drug Discov.,2015(14),445-447；
[6]Wenling,Qin,Mauro Panunizo and Stefano Biondi,Antibiotics,2014(3),193-215；
发明内容
本发明提供式(I)所示化合物或其药学上可接受的盐，
Figure PCTCN2017087004-appb-000003
其中，
m为1或2；
n为1或2；
i为1、2或3。
在本发明的一些方案中，上述化合物或其药学上可接受的盐，选自
本发明还提供一种药物组合物，其含有治疗有效量根据权利要求上述的化合物或其药学上可接受的盐和药学上可接受的载体。
本发明还提供上述的化合物或其药学上可接受的盐或上述的药物组合物在制备用于治疗细菌感染的β-内酰胺酶抑制剂中的应用。
定义和说明
除非另有说明，本文所用的下列术语和短语旨在具有下列含义。一个特定的术语或短语在没有特别定义的情况下不应该被认为是不确定的或不清楚的，而应该按照普通的含义去理解。当本文中出现商品名时，意在指代其对应的商品或其活性成分。这里所采用的术语“药学上可接受的”，是针对那些化合物、材料、组合物和/或剂型而言，它们在可靠的医学判断的范围之内，适用于与人类和动物的组织接触使用，而没有过多的毒性、刺激性、过敏性反应或其它问题或并发症，与合理的利益/风险比相称。
术语“药学上可接受的盐”是指本发明化合物的盐，由本发明发现的具有特定取代基的化合物与相对无 毒的酸或碱制备。当本发明的化合物中含有相对酸性的功能团时，可以通过在纯的溶液或合适的惰性溶剂中用足够量的碱与这类化合物的中性形式接触的方式获得碱加成盐。药学上可接受的碱加成盐包括钠、钾、钙、铵、有机氨或镁盐或类似的盐。当本发明的化合物中含有相对碱性的官能团时，可以通过在纯的溶液或合适的惰性溶剂中用足够量的酸与这类化合物的中性形式接触的方式获得酸加成盐。药学上可接受的酸加成盐的实例包括无机酸盐，所述无机酸包括例如盐酸、氢溴酸、硝酸、碳酸，碳酸氢根，磷酸、磷酸一氢根、磷酸二氢根、硫酸、硫酸氢根、氢碘酸、亚磷酸等；以及有机酸盐，所述有机酸包括如乙酸、丙酸、异丁酸、马来酸、丙二酸、苯甲酸、琥珀酸、辛二酸、反丁烯二酸、乳酸、扁桃酸、邻苯二甲酸、苯磺酸、对甲苯磺酸、柠檬酸、酒石酸和甲磺酸等类似的酸；还包括氨基酸(如精氨酸等)的盐，以及如葡糖醛酸等有机酸的盐(参见Berge et al.,"Pharmaceutical Salts",Journal of Pharmaceutical Science 66:1-19(1977))。本发明的某些特定的化合物含有碱性和酸性的官能团，从而可以被转换成任一碱或酸加成盐。
优选地，以常规方式使盐与碱或酸接触，再分离母体化合物，由此再生化合物的中性形式。化合物的母体形式与其各种盐的形式的不同之处在于某些物理性质，例如在极性溶剂中的溶解度不同。
本文所用的“药学上可接受的盐”属于本发明化合物的衍生物，其中，通过与酸成盐或与碱成盐的方式修饰所述母体化合物。药学上可接受的盐的实例包括但不限于：碱基比如胺的无机酸或有机酸盐、酸根比如羧酸的碱金属或有机盐等等。药学上可接受的盐包括常规的无毒性的盐或母体化合物的季铵盐，例如无毒的无机酸或有机酸所形成的盐。常规的无毒性的盐包括但不限于那些衍生自无机酸和有机酸的盐，所述的无机酸或有机酸选自2-乙酰氧基苯甲酸、2-羟基乙磺酸、乙酸、抗坏血酸、苯磺酸、苯甲酸、碳酸氢根、碳酸、柠檬酸、依地酸、乙烷二磺酸、乙烷磺酸、富马酸、葡庚糖、葡糖酸、谷氨酸、乙醇酸、氢溴酸、盐酸、氢碘酸盐、羟基、羟萘、羟乙磺酸、乳酸、乳糖、十二烷基磺酸、马来酸、苹果酸、扁桃酸、甲烷磺酸、硝酸、草酸、双羟萘酸、泛酸、苯乙酸、磷酸、多聚半乳糖醛、丙酸、水杨酸、硬脂酸、亚乙酸、琥珀酸、氨基磺酸、对氨基苯磺酸、硫酸、单宁、酒石酸和对甲苯磺酸。
本发明的药学上可接受的盐可由含有酸根或碱基的母体化合物通过常规化学方法合成。一般情况下，这样的盐的制备方法是：在水或有机溶剂或两者的混合物中，经由游离酸或碱形式的这些化合物与化学计量的适当的碱或酸反应来制备。一般地，优选醚、乙酸乙酯、乙醇、异丙醇或乙腈等非水介质。
除了盐的形式，本发明所提供的化合物还存在前药形式。本文所描述的化合物的前药容易地在生理条件下发生化学变化从而转化成本发明的化合物。此外，前体药物可以在体内环境中通过化学或生化方法被转换到本发明的化合物。
本发明的某些化合物可以以非溶剂化形式或者溶剂化形式存在，包括水合物形式。一般而言，溶剂化形式与非溶剂化的形式相当，都包含在本发明的范围之内。
本发明的某些化合物可以具有不对称碳原子(光学中心)或双键。外消旋体、非对映异构体、几何异构体和单个的异构体都包括在本发明的范围之内。
本文中消旋体、ambiscalemic and scalemic或者对映体纯的化合物的图示法来自Maehr,J.Chem.Ed.1985,62:114-120。1985年，62：114-120。除非另有说明，用楔形键和虚线键表示一个立体中心的绝对构型。当本文所述化合物含有烯属双键或其它几何不对称中心，除非另有规定，它们包括E、Z几何异构体。同样地，所有的互变异构形式均包括在本发明的范围之内。
本发明的化合物可以存在特定的几何或立体异构体形式。本发明设想所有的这类化合物，包括顺式和反式异构体、(-)-和(+)-对对映体、(R)-和(S)-对映体、非对映异构体、(D)-异构体、(L)-异构体，及其外消旋混合物和其他混合物，例如对映异构体或非对映体富集的混合物，所有这些混合物都属于本发明的范围之内。烷基等取代基中可存在另外的不对称碳原子。所有这些异构体以及它们的混合物，均包括在本发明的范围之内。
可以通过的手性合成或手性试剂或者其他常规技术制备光学活性的(R)-和(S)-异构体以及D和L异构体。如果想得到本发明某化合物的一种对映体，可以通过不对称合成或者具有手性助剂的衍生作用来制备，其中将所得非对映体混合物分离，并且辅助基团裂开以提供纯的所需对映异构体。或者，当分子中含有碱性官能团(如氨基)或酸性官能团(如羧基)时，与适当的光学活性的酸或碱形成非对映异构体的盐，然后通过本领域所公知的常规方法进行非对映异构体拆分，然后回收得到纯的对映体。此外，对映异构体和非对映异构体的分离通常是通过使用色谱法完成的，所述色谱法采用手性固定相，并任选地与化学衍生法相结合(例如由胺生成氨基甲酸盐)。
本发明的化合物可以在一个或多个构成该化合物的原子上包含非天然比例的原子同位素。例如，可用放射性同位素标记化合物，比如氚(3H)，碘-125(125I)或C-14(14C)。本发明的化合物的所有同位素组成的变换，无论放射性与否，都包括在本发明的范围之内。
术语“药学上可接受的载体”是指能够递送本发明有效量活性物质、不干扰活性物质的生物活性并且对宿主或者患者无毒副作用的任何制剂或载体介质代表性的载体包括水、油、蔬菜和矿物质、膏基、洗剂基质、软膏基质等。这些基质包括悬浮剂、增粘剂、透皮促进剂等。它们的制剂为化妆品领域或局部药物领域的技术人员所周知。关于载体的其他信息，可以参考Remington:The Science and Practice of Pharmacy,21st Ed.,Lippincott,Williams&Wilkins(2005)，该文献的内容通过引用的方式并入本文。
术语“赋形剂”通常是指配制有效的药物组合物所需要载体、稀释剂和/或介质。
针对药物或药理学活性剂而言，术语“有效量”或“治疗有效量”是指无毒的但能达到预期效果的药物或药剂的足够用量。对于本发明中的口服剂型，组合物中一种活性物质的“有效量”是指与该组合物中另一种活性物质联用时为了达到预期效果所需要的用量。有效量的确定因人而异，取决于受体的年龄和一般情况，也取决于具体的活性物质，个案中合适的有效量可以由本领域技术人员根据常规试验确定。
术语“活性成分”、“治疗剂”，“活性物质”或“活性剂”是指一种化学实体，它可以有效地治疗目标紊乱、疾病或病症。
“任选”或“任选地”指的是随后描述的事件或状况可能但不是必需出现的，并且该描述包括其中所述事件或状况发生的情况以及所述事件或状况不发生的情况。
术语“被取代的”是指特定原子上的任意一个或多个氢原子被取代基取代，可以包括重氢和氢的变体，只要特定原子的价态是正常的并且取代后的化合物是稳定的。当取代基为酮基(即＝O)时，意味着两个氢原子被取代。酮取代不会发生在芳香基上。术语“任选被取代的”是指可以被取代，也可以不被取代，除非另有规定，取代基的种类和数目在化学上可以实现的基础上可以是任意的。
当任何变量(例如R)在化合物的组成或结构中出现一次以上时，其在每一种情况下的定义都是独立的。因此，例如，如果一个基团被0-2个R所取代，则所述基团可以任选地至多被两个R所取代，并且每 种情况下的R都有独立的选项。此外，取代基和/或其变体的组合只有在这样的组合会产生稳定的化合物的情况下才是被允许的。
当一个连接基团的数量为0时，比如-(CRR)0-，表示该连接基团为单键。
当其中一个变量选自单键时，表示其连接的两个基团直接相连，比如A-L-Z中L代表单键时表示该结构实际上是A-Z。
当一个取代基为空缺时，表示该取代基是不存在的，比如A-X中X为空缺时表示该结构实际上是A。当一个取代基的键可以交叉连接到一个环上的两个原子时，这种取代基可以与这个环上的任意原子相键合。当所列举的取代基中没有指明其通过哪一个原子连接到化学结构通式中包括但未具体提及的化合物时，这种取代基可以通过其任何原子相键合。取代基和/或其变体的组合只有在这样的组合会产生稳定的化合物的情况下才是被允许的。例如，结构单元
Figure PCTCN2017087004-appb-000005
表示其可在环己基或者环己二烯上的任意一个位置发生取代。
除非另有规定，术语“杂”表示杂原子或杂原子团(即含有杂原子的原子团)，包括碳(C)和氢(H)以外的原子以及含有这些杂原子的原子团，例如包括氧(O)、氮(N)、硫(S)、硅(Si)、锗(Ge)、铝(Al)、硼(B)、-O-、-S-、＝O、＝S、-C(＝O)O-、-C(＝O)-、-C(＝S)-、-S(＝O)、-S(＝O)2-，以及任选被取代的-C(＝O)N(H)-、-N(H)-、-C(＝NH)-、-S(＝O)2N(H)-或-S(＝O)N(H)-。
除非另有规定，“环”表示被取代或未被取代的环烷基、杂环烷基、环烯基、杂环烯基、环炔基、杂环炔基、芳基或杂芳基。所谓的环包括单环、联环、螺环、并环或桥环。环上原子的数目通常被定义为环的元数，例如，“5～7元环”是指环绕排列5～7个原子。除非另有规定，该环任选地包含1～3个杂原子。因此，“5～7元环”包括例如苯基、吡啶和哌啶基；另一方面，术语“5～7元杂环烷基环”包括吡啶基和哌啶基，但不包括苯基。术语“环”还包括含有至少一个环的环系，其中的每一个“环”均独立地符合上述定义。
除非另有规定，术语“杂环”或“杂环基”意指稳定的含杂原子或杂原子团的单环、双环或三环，它们可以是饱和的、部分不饱和的或不饱和的(芳族的)，它们包含碳原子和1、2、3或4个独立地选自N、O和S的环杂原子，其中上述任意杂环可以稠合到一个苯环上形成双环。氮和硫杂原子可任选被氧化(即NO和S(O)p，p是1或2)。氮原子可以是被取代的或未取代的(即N或NR，其中R是H或本文已经定义过的其他取代基)。该杂环可以附着到任何杂原子或碳原子的侧基上从而形成稳定的结构。如果产生的化合物是稳定的，本文所述的杂环可以发生碳位或氮位上的取代。杂环中的氮原子任选地被季铵化。一个优选方案是，当杂环中S及O原子的总数超过1时，这些杂原子彼此不相邻。另一个优选方案是，杂环中S及O原子的总数不超过1。如本文所用，术语“芳族杂环基团”或“杂芳基”意指稳定的5、6、7元单环或双环或7、8、9或10元双环杂环基的芳香环，它包含碳原子和1、2、3或4个独立地选自N、O和S的环杂原子。氮原子可以是被取代的或未取代的(即N或NR，其中R是H或本文已经定义过的其他取代基)。氮和硫杂原子可任选被氧化(即NO和S(O)p，p是1或2)。值得注意的是，芳香杂环上S和O原子的总数不超过1。桥环也包含在杂环的定义中。当一个或多个原子(即C、O、N或S)连接两个不相邻的碳原子或氮原子时形成桥环。优选的桥环包括但不限于：一个碳原子、两个碳原子、一个氮原子、两个氮原子和一个碳-氮基。值得注意的是，一个桥总是将单环转换成三环。桥环中，环上的取代基也可以出现在桥上。
杂环化合物的实例包括但不限于：吖啶基、吖辛因基、苯并咪唑基、苯并呋喃基、苯并巯基呋喃基、苯并巯基苯基、苯并恶唑基、苯并恶唑啉基、苯并噻唑基、苯并三唑基、苯并四唑基、苯并异恶唑基、苯并异噻唑基、苯并咪唑啉基、咔唑基、4aH-咔唑基、咔啉基、苯并二氢吡喃基、色烯、噌啉基十氢喹啉基、2H,6H-1,5,2-二噻嗪基、二氢呋喃并[2,3-b]四氢呋喃基、呋喃基、呋咱基、咪唑烷基、咪唑啉基、咪唑基、1H-吲唑基、吲哚烯基、二氢吲哚基、中氮茚基、吲哚基、3H-吲哚基、异苯并呋喃基、异吲哚基、异二氢吲哚基、异喹啉基、异噻唑基、异恶唑基、亚甲二氧基苯基、吗啉基、萘啶基，八氢异喹啉基、恶二唑基、1,2,3-恶二唑基、1,2,4-恶二唑基、1,2,5-恶二唑基、1,3,4-恶二唑基、恶唑烷基、恶唑基、羟吲哚基、嘧啶基、菲啶基、菲咯啉基、吩嗪、吩噻嗪、苯并黄嘌呤基、酚恶嗪基、酞嗪基、哌嗪基、哌啶基、哌啶酮基、4-哌啶酮基、胡椒基、蝶啶基、嘌呤基、吡喃基、吡嗪基、吡唑烷基、吡唑啉基、吡唑基、哒嗪基、吡啶并恶唑、吡啶并咪唑、吡啶并噻唑、吡啶基、吡咯烷基、吡咯啉基、2H-吡咯基、吡咯基、喹唑啉基、喹啉基、4H-喹嗪基、喹喔啉基、奎宁环基、四氢呋喃基、四氢异喹啉基、四氢喹啉基、四唑基，6H-1,2,5-噻二嗪基、1,2,3-噻二唑基、1,2,4-噻二唑基、1,2,5-噻二唑基、1,3,4-噻二唑基、噻蒽基、噻唑基、异噻唑基噻吩基、噻吩并恶唑基、噻吩并噻唑基、噻吩并咪唑基、噻吩基、三嗪基、1,2,3-三唑基、1,2,4-三唑基、1,2,5-三唑基、1,3,4-三唑基和呫吨基。还包括稠环和螺环化合物。
除非另有规定，术语“烃基”或者其下位概念(比如烷基、烯基、炔基、芳基等等)本身或者作为另一取代基的一部分表示直链的、支链的或环状的烃原子团或其组合，可以是完全饱和的(如烷基)、单元或多元不饱和的(如烯基、炔基、芳基)，可以是单取代或多取代的，可以是一价(如甲基)、二价(如亚甲基)或者多价(如次甲基)，可以包括二价或多价原子团，具有指定数量的碳原子(如C1-C12表示1至12个碳，C1-12选自C1、C2、C3、C4、C5、C6、C7、C8、C9、C10、C11和C12；C3-12选自C3、C4、C5、C6、C7、C8、C9、C10、C11和C12。)。“烃基”包括但不限于脂肪烃基和芳香烃基，所述脂肪烃基包括链状和环状，具体包括但不限于烷基、烯基、炔基，所述芳香烃基包括但不限于6-12元的芳香烃基，例如苯、萘等。在一些实施例中，术语“烃基”表示直链的或支链的原子团或它们的组合，可以是完全饱和的、单元或多元不饱和的，可以包括二价和多价原子团。饱和烃原子团的实例包括但不限于甲基、乙基、正丙基、异丙基、正丁基、叔丁基、异丁基、仲丁基、异丁基、环己基、(环己基)甲基、环丙基甲基，以及正戊基、正己基、正庚基、正辛基等原子团的同系物或异构体。不饱和烃基具有一个或多个双键或三键，其实例包括但不限于乙烯基、2-丙烯基、丁烯基、巴豆基、2-异戊烯基、2-(丁二烯基)、2，4-戊二烯基、3-(1，4-戊二烯基)、乙炔基、1-和3-丙炔基，3-丁炔基，以及更高级的同系物和异构体。
除非另有规定，术语“杂烃基”或者其下位概念(比如杂烷基、杂烯基、杂炔基、杂芳基等等)本身或者与另一术语联合表示稳定的直链的、支链的或环状的烃原子团或其组合，有一定数目的碳原子和至少一个杂原子组成。在一些实施例中，术语“杂烷基”本身或者与另一术语联合表示稳定的直链的、支链的烃原子团或其组合物，有一定数目的碳原子和至少一个杂原子组成。在一个典型实施例中，杂原子选自B、O、N和S，其中氮和硫原子任选地被氧化，氮杂原子任选地被季铵化。杂原子或杂原子团可以位于杂烃基的任何内部位置，包括该烃基附着于分子其余部分的位置，但术语“烷氧基”、“烷氨基”和“烷硫基”(或硫代烷氧基)属于惯用表达，是指分别通过一个氧原子、氨基或硫原子连接到分子的其余部分的那些烷基基团。实例包括但不限于-CH2-CH2-O-CH3、-CH2-CH2-NH-CH3、-CH2-CH2-N(CH3)-CH3、-CH2-S-CH2-CH3、 -CH2-CH2、-S(O)-CH3、-CH2-CH2-S(O)2-CH3、-CH＝CH-O-CH3、-CH2-CH＝N-OCH3和–CH＝CH-N(CH3)-CH3。至多两个杂原子可以是连续的，例如-CH2-NH-OCH3。
除非另有规定，术语“环烃基”、“杂环烃基”或者其下位概念(比如芳基、杂芳基、环烷基、杂环烷基、环烯基、杂环烯基、环炔基、杂环炔基等等)本身或与其他术语联合分别表示环化的“烃基”、“杂烃基”。此外，就杂烃基或杂环烃基(比如杂烷基、杂环烷基)而言，杂原子可以占据该杂环附着于分子其余部分的位置。环烃基的实例包括但不限于环戊基、环己基、1-环己烯基、3-环己烯基、环庚基等。杂环基的非限制性实例包括1-(1,2,5,6-四氢吡啶基)、1-哌啶基、2-哌啶基，3-哌啶基、4-吗啉基、3-吗啉基、四氢呋喃-2-基、四氢呋喃吲哚-3-基、四氢噻吩-2-基、四氢噻吩-3-基，1-哌嗪基和2-哌嗪基。
除非另有规定，术语“烷基”用于表示直链或支链的饱和烃基,可以是单取代(如-CH2F)或多取代的(如-CF3)，可以是一价(如甲基)、二价(如亚甲基)或者多价(如次甲基)。烷基的例子包括甲基(Me)，乙基(Et)，丙基(如，n-丙基和异丙基)，丁基(如，n-丁基，异丁基，s-丁基，t-丁基)，戊基(如，n-戊基，异戊基，新戊基)等。
除非另有规定，“烯基”指在链的任何位点上具有一个或多个碳碳双键的烷基,可以是单取代或多取代的，可以是一价、二价或者多价。烯基的例子包括乙烯基，丙烯基，丁烯基，戊烯基，己烯基，丁间二烯基，戊间二烯基，己间二烯基等。
除非另有规定，“炔基”指在链的任何位点上具有一个或多个碳碳三键的烷基，可以是单取代或多取代的，可以是一价、二价或者多价。炔基的例子包括乙炔基，丙炔基，丁炔基，戊炔基等。
除非另有规定，环烷基包括任何稳定的环状或多环烃基，任何碳原子都是饱和的，可以是单取代或多取代的，可以是一价、二价或者多价。这些环烷基的实例包括，但不限于，环丙基、降冰片烷基、[2.2.2]二环辛烷、[4.4.0]二环癸烷等。
除非另有规定，环烯基包括任何稳定的环状或多环烃基，该烃基在环的任何位点含有一个或多个不饱和的碳-碳双键，可以是单取代或多取代的，可以是一价、二价或者多价。这些环烯基的实例包括，但不限于，环戊烯基、环己烯基等。
除非另有规定，环炔基包括任何稳定的环状或多环烃基，该烃基在环的任何位点含有一个或多个碳-碳三键，可以是单取代或多取代的，可以是一价、二价或者多价。
除非另有规定，术语“卤代素”或“卤素”本身或作为另一取代基的一部分表示氟、氯、溴或碘原子。此外，术语“卤代烷基”意在包括单卤代烷基和多卤代烷基。例如，术语“卤代(C1-C4)烷基”意在包括但不仅限于三氟甲基、2，2，2-三氟乙基、4-氯丁基和3-溴丙基等等。除非另有规定，卤代烷基的实例包括但不仅限于：三氟甲基、三氯甲基、五氟乙基，和五氯乙基。
“烷氧基”代表通过氧桥连接的具有特定数目碳原子的上述烷基，除非另有规定，C1-6烷氧基包括C1、C2、C3、C4、C5和C6的烷氧基。烷氧基的例子包括但不限于：甲氧基、乙氧基、正丙氧基、异丙氧基、正丁氧基、仲丁氧基、叔丁氧基、正戊氧基和S-戊氧基。除非另有规定，术语“芳基”表示多不饱和的芳族烃取代基，可以是单取代或多取代的，可以是一价、二价或者多价，它可以是单环或多环(比如1至3个环；其中至少一个环是芳族的)，它们稠合在一起或共价连接。术语“杂芳基”是指含有一至四个杂原子的芳基(或环)。在一个示范性实例中，杂原子选自B、N、O和S，其中氮和硫原子任选地被氧化，氮原 子任选地被季铵化。杂芳基可通过杂原子连接到分子的其余部分。芳基或杂芳基的非限制性实施例包括苯基、1-萘基、2-萘基、4-联苯基、1-吡咯基、2-吡咯基、3-吡咯基、3-吡唑基、2-咪唑基、4-咪唑基、吡嗪基、2-恶唑基、4-恶唑基、2-苯基-4-恶唑基、5-恶唑基、3-异恶唑基、4-异恶唑基、5-异恶唑基、2-噻唑基、4-噻唑基、5-噻唑基、2-呋喃基、3-呋喃基、2-噻吩基、3-噻吩基、2-吡啶基、3-吡啶基、4-吡啶基、2-嘧啶基、4-嘧啶基、5-苯并噻唑基、嘌呤基、2-苯并咪唑基、5-吲哚基、1-异喹啉基、5-异喹啉基、2-喹喔啉基、5-喹喔啉基、3-喹啉基和6-喹啉基。上述任意一个芳基和杂芳基环系的取代基选自下文所述的可接受的取代基。
除非另有规定，芳基在与其他术语联合使用时(例如芳氧基、芳硫基、芳烷基)包括如上定义的芳基和杂芳基环。因此，术语“芳烷基”意在包括芳基附着于烷基的那些原子团(例如苄基、苯乙基、吡啶基甲基等)，包括其中碳原子(如亚甲基)已经被例如氧原子代替的那些烷基，例如苯氧基甲基、2-吡啶氧甲基3-(1-萘氧基)丙基等。
术语“离去基团”是指可以被另一种官能团或原子通过取代反应(例如亲和取代反应)所取代的官能团或原子。例如，代表性的离去基团包括三氟甲磺酸酯；氯、溴、碘；磺酸酯基，如甲磺酸酯、甲苯磺酸酯、对溴苯磺酸酯、对甲苯磺酸酯等；酰氧基，如乙酰氧基、三氟乙酰氧基等等。
术语“保护基”包括但不限于“氨基保护基”、“羟基保护基”或“巯基保护基”。术语“氨基保护基”是指适合用于阻止氨基氮位上副反应的保护基团。代表性的氨基保护基包括但不限于：甲酰基；酰基，例如链烷酰基(如乙酰基、三氯乙酰基或三氟乙酰基)；烷氧基羰基，如叔丁氧基羰基(Boc)；芳基甲氧羰基，如苄氧羰基(Cbz)和9-芴甲氧羰基(Fmoc)；芳基甲基，如苄基(Bn)、三苯甲基(Tr)、1,1-二-(4'-甲氧基苯基)甲基；甲硅烷基，如三甲基甲硅烷基(TMS)和叔丁基二甲基甲硅烷基(TBS)等等。术语“羟基保护基”是指适合用于阻止羟基副反应的保护基。代表性羟基保护基包括但不限于：烷基，如甲基、乙基和叔丁基；酰基，例如链烷酰基(如乙酰基)；芳基甲基，如苄基(Bn)，对甲氧基苄基(PMB)、9-芴基甲基(Fm)和二苯基甲基(二苯甲基，DPM)；甲硅烷基，如三甲基甲硅烷基(TMS)和叔丁基二甲基甲硅烷基(TBS)等等。
本发明的化合物可以通过本领域技术人员所熟知的多种合成方法来制备，包括下面列举的具体实施方式、其与其他化学合成方法的结合所形成的实施方式以及本领域技术上人员所熟知的等同替换方式，优选的实施方式包括但不限于本发明的实施例。
本发明所使用的溶剂可经市售获得。本发明采用下述缩略词：aq代表水；HATU代表O-(7-氮杂苯并三唑-1-基)-N，N，N'，N'-四甲基脲六氟磷酸盐；EDC代表N-(3-二甲基氨基丙基)-N'-乙基碳二亚胺盐酸盐；m-CPBA代表3-氯过氧苯甲酸；eq代表当量、等量；CDI代表羰基二咪唑；DCM代表二氯甲烷；PE代表石油醚；DIAD代表偶氮二羧酸二异丙酯；DMF代表N，N-二甲基甲酰胺；DMSO代表二甲亚砜；EtOAc代表乙酸乙酯；EtOH代表乙醇；MeOH代表甲醇；CBz代表苄氧羰基，是一种胺保护基团；BOC代表叔丁基羰基是一种胺保护基团；HOAc代表乙酸；NaCNBH3代表氰基硼氢化钠；r.t.代表室温；O/N代表过夜；THF代表四氢呋喃；Boc2O代表二-叔丁基二碳酸酯；TFA代表三氟乙酸；DIPEA代表二异丙基乙基胺；SOCl2代表氯化亚砜；CS2代表二硫化碳；TsOH代表对甲苯磺酸；NFSI代表N-氟-N-(苯磺酰基)苯磺酰胺；NCS代表1-氯吡咯烷-2,5-二酮；n-Bu4NF代表氟化四丁基铵；iPrOH代表2-丙醇；mp 代表熔点；LDA代表二异丙基胺基锂。
化合物经手工或者
Figure PCTCN2017087004-appb-000006
软件命名，市售化合物采用供应商目录名称。
附图说明
图1为化合物1与参照化合物OP-0595在小鼠大腿肌肉感染模型中的药效比较。
图2为化合物1-H2与参照化合物OP-0595在小鼠大腿肌肉感染模型中的药效量效关系比较。
具体实施方式
下面通过实施例对本发明进行详细描述，但并不意味着对本发明任何不利限制。本文已经详细地描述了本发明，其中也公开了其具体实施例方式，对本领域的技术人员而言，在不脱离本发明精神和范围的情况下针对本发明具体实施方式进行各种变化和改进将是显而易见的。
实施例1:化合物1
Figure PCTCN2017087004-appb-000007
步骤1：
把三甲基碘化亚砜(12.00克，54.53毫摩尔)溶解在80毫升N,N-二甲基甲酰胺和40毫升四氢呋喃的混合溶液中，然后冷却到0℃，在氮气保护下分批缓慢加入60％的钠氢(2.16克，54毫摩尔)，然后升温到20-25℃搅拌30分钟。澄清的的反应液随后冷却到-78℃，缓慢滴加溶解在40毫升四氢呋喃的1-A(10.00克，54毫摩尔)溶液，加完后，反应混合物缓慢升温到20-25℃，并搅拌90分钟。薄层色谱(石油醚/乙酸乙酯＝5/1)跟踪反应显示反应结束，反应也用100毫升乙酸乙酯稀释，然后倒入500毫升冰水中，分层后水相用乙酸乙酯萃取三次，每次100毫升。合并的有机相用饱和食盐水洗涤后，用无水硫酸钠干燥，过滤，将滤液减压 浓缩得到粗品，粗品用柱层析法(石油醚/乙酸乙酯＝10/1到5/1梯度洗脱)分离纯化得到化合物1-B(4.5克，收率42％)。
步骤2：
在15℃下，把化合物1-B(500毫克，2.51毫摩尔)和N-羟基邻苯二甲酰亚胺1-1(491.23毫克，3.01毫摩尔)溶解在15毫升N,N-二甲基甲酰胺中，氮气保护下一次性加入三乙胺(304.71毫克，3.01毫摩尔)，然后将反应混合物加热到90℃并搅拌2小时，薄层色谱分析显示反应完成，把反应降温到15℃并用30毫升乙酸乙酯稀释，然后用30毫升水洗涤1次，用饱和食盐水洗涤2次，每次30毫升，有机层用无水硫酸钠干燥后减压浓缩得到化合物1-C的粗品800毫克。
1H NMR(400MHz,CDCl3)δ7.89(d,J＝2.8Hz,2H),7.85-7.78(m,2H),4.41-4.25(m,2H),3.84-3.76(m,2H),3.63-3.38(m,5H),2.61(t,J＝7.6Hz,1H),1.97(d,J＝12.0Hz,1H),1.48(s,9H).
步骤3：
在15℃下，把上述化合物1-C(700毫克，1.92毫摩尔)溶解在20毫升甲醇中，氮气保护下一次性加入一水合肼(961.66毫克，19.20毫摩尔)，然后把反应混合物加热到50℃并搅拌1小时，薄层色谱跟踪反应显示反应完成，反应液随后冷却到15℃并过滤，滤液减压浓缩得到粗品，粗品用柱层析法(乙酸乙酯/石油醚混合液，梯度50％～100％)分离纯化得到氧胺化合物1-D(600毫克，收率51％)。
步骤4：
在15℃下，把化合物1-D(350毫克，1.51毫摩尔)和(2S,5R)-6-苄氧基-7-氧-1,6-二氮杂二环[3.2.1]辛-2-羧酸1-2(438.06毫克，1.59毫摩尔)(合成方法参考专利WO2012172368A1)溶解在20毫升二氯甲烷中，然后加入EDCI(376.31毫克，1.96毫摩尔)和HOBt(265.24毫克，1.96毫摩尔)，最后加入二异丙基乙胺(292.73毫克，2.27毫摩尔)，反应混合物在氮气保护下搅拌16小时，LCMS跟踪显示反应完成，减压浓缩移除二氯甲烷，粗品用柱层析(乙酸乙酯/石油醚梯度洗脱，50％～100％)精制得到缩合化合物1-E(300毫克，收率27％)。利用常规的超临界色谱技术(SFC)将1-E拆分成两个非对映异构体化合物1-E1(保留时间为2.80分钟)和1-E2(保留时间为3.40分钟)。
步骤5：
在15℃下，把化合物1-E(300毫克，0.611毫摩尔)溶解在15毫升四氢呋喃中，氮气保护下加入100毫克10％的干钯碳，氢气置换三次后，在氢气球氛围下混合物于15℃搅拌4小时，薄层色谱跟踪显示反应结束，催化剂用硅藻土过滤，浓缩滤液得到化合物1-F(240毫克，收率98％)。用相同的方法，由1-E1合成得到化合物1-F1，用1-E2合成得到化合物1-F2。
步骤6：
在15℃下，把化合物1-F(240毫克，0.599毫摩尔)溶解在5毫升异丙醇和5毫升水的混合溶液中，氮气保护下一次性加入N,N-二甲基甲酰胺的三氧化硫络合物(100.09毫克，0.719毫摩尔)，随后加入三乙胺(15.16毫克，0.15毫摩尔)，反应混合物在15℃下搅拌16小时，LCMS跟踪显示反应结束，将异丙醇在室温下浓缩，再加入饱和磷酸二氢钠溶液30毫升调节pH值到6左右，然后用石油醚/乙酸乙酯＝2:1的混合溶液洗涤两次，每次20毫升，然后加入四丁基硫酸氢铵(407毫克，1.2毫摩尔)，该溶液用乙酸乙酯萃取3次，每次20毫升，合并的有机相用20毫升饱和食盐水洗涤1次，然后用无水硫酸钠干燥，过滤浓缩得到粗品。粗品用薄层析精制(乙酸乙酯/丙酮梯度洗脱，0～66％)得到化合物1-G(260毫克，收率 60％)。用相同的方法，由1-F1合成得到化合物1-G1，由1-F2合成得到化合物1-G2。
步骤7：
把化合物1-G(260毫克，0.36毫摩尔)溶解在10毫升无水二氯甲烷中，然后冷却到0℃，氮气保护下加入三氟乙酸(1.38克，12.08毫摩尔)，然后把反应液升温到15℃并搅拌1小时，LCMS跟踪显示反应完成，在15℃下减压浓缩除掉二氯甲烷和三氟乙酸，粗品用乙腈打浆过滤3次，除掉杂质和大部分三氟乙酸，最后得到的固体用水溶解冻干得化合物1(83毫克，收率59％，纯度97％)。1H NMR(400MHz,D2O)δ4.13(d,J＝3.0Hz,1H),4.06(t,J＝2.2Hz,2H),3.99(d,J＝6.0Hz,1H),3.51-3.41(m,2H),3.35-3.29(m,2H),3.24(d,J＝12.0Hz,1H),3.05(d,J＝12.2Hz,1H),2.15-1.95(m,4H),1.93-1.81(m,1H),1.80-1.68(m,1H).LCMS(ESI)m/z:379.0(M-1)；
用相同的方法，由化合物1-G1合成得到化合物1-H1。1H NMR(400MHz,D2O)δ4.14(br.s.,1H),4.11-4.02(m,2H),4.00(d,J＝7.0Hz,1H),3.53-3.42(m,2H),3.33(s,2H),3.25(d,J＝11.6Hz,1H),3.06(d,J＝12.2Hz,1H),2.18-2.00(m,4H),1.88(dt,J＝7.6,15.6Hz,1H),1.82-1.68(m,1H)；LCMS(ESI)m/z:379.0(M-1)；
用相同的方法，由化合物1-G2合成得到化合物1-H2。1H NMR(400MHz,D2O)δ4.15(br.s.,1H),4.08(s,2H),4.02(d,J＝7.0Hz,1H),3.47(d,J＝7.6Hz,2H),3.37-3.32(m,2H),3.27(d,J＝12.0Hz,1H),3.08(d,J＝12.2Hz,1H),2.17-2.03(m,4H),1.96-1.84(m,1H),1.84-1.71(m,1H).LCMS(ESI)m/z:379.0(M-1)；
实施例2:化合物2
Figure PCTCN2017087004-appb-000008
化合物2以1-叔丁氧羰基-3-氮杂环丁酮(2-A)为起始原料，采用与实施例1相同方法合成得到。1H NMR(400MHz,D2O)δ4.23(d,J＝10.4Hz,2H),4.15-3.98(m,6H),3.25(d,J＝11.4Hz,1H),3.16-3.02(m,1H),2.09(d,J＝15.0Hz,1H),2.05-1.99(m,1H),1.91-1.82(m,1H),1.79(d,J＝7.0Hz,1H),LCMS(ESI)m/z:365.0(M-1)；
实施例3:化合物3
Figure PCTCN2017087004-appb-000009
化合物3以1-叔丁氧羰基-4-哌啶酮(3-A)为起始原料，采用与实施例1相同方法合成得到。1H NMR(400MHz,D2O)δ4.16(br,1H),4.02(br,1H),3.88(s 2H),3.27(br,5H),3.11(br,1H),2.01(br,3H),1.87(br,5H).LCMS(ESI)m/z:493.1(M-1).
实施例4:化合物4
Figure PCTCN2017087004-appb-000010
步骤1：
把活化锌粉(12.41克，189.87毫摩尔)悬浮在150毫升四氢呋喃中，在35℃下加入三甲基氯硅烷(317.31毫克，2.92毫摩尔，0.369毫升)，然后氮气保护下在66℃下缓慢滴加溴乙酸乙酯(9.27克，55.5毫摩尔，6.14毫升)，在反应过程中，悬浮物逐渐变成橘黄色的澄清溶液，等锌粉完全溶解后冷却到20℃转移到滴液漏斗中，在0℃下缓慢加到2-A(5克，29.21毫摩尔)的四氢呋喃(80毫升)中，滴加完成后，反应混合物在0℃搅拌1.5小时，LCMS显示反应完成，反应溶剂减压浓缩，残留物溶解在100毫升乙酸乙酯中，再用1摩尔/升的盐酸水溶液(50毫升)洗涤一次，饱和食盐水洗涤三次，每次40毫升，然后用无水硫酸钠干燥，过滤浓缩得到粗品，粗品用柱层析分离纯化得到化合物4-B(1.4克，收率18％)。1H NMR(400MHz,CDCl3)δ4.22(q,J＝7.0Hz,2H),3.95(d,J＝9.4Hz,2H),3.83(d,J＝9.6Hz,2H),2.83(s,2H),1.45(s,9H),1.34-1.29(m,3H)
步骤2：
在15℃下，把化合物4-B(1.5克，5.78毫摩尔)溶解在35毫升无水四氢呋喃中，氮气保护下分批加入硼氢化锂(503.55毫克，23.12毫摩尔)，反应混合物在15℃下搅拌2小时，薄层色谱(石油醚/乙酸乙酯＝2/1)跟踪显示反应完成，反应用饱和柠檬酸溶液淬灭并调节pH值到7左右，然后加入乙酸乙酯100毫升稀释分层。有机相用饱和食盐水洗涤2次，每次40毫升，然后用无水硫酸钠干燥，再过滤浓缩得到 800毫克粗品化合物4-C。1H NMR(400MHz,CDCl3)δ4.60-4.52(m,1H),3.96-3.81(m,6H),3.10-2.96(m,1H),2.01(t,J＝5.4Hz,2H),1.43(s,9H)
步骤3：
把化合物4-C(850毫克，3.91毫摩尔)，N-羟基邻苯二甲酰亚胺1-1(701.62毫克，4.3毫摩尔)和三苯基磷(1.54克，5.87毫摩尔)溶解在30毫升四氢呋喃中，然后冷却到0℃，氮气保护下10分钟内滴加完偶氮二甲酸二异丙酯(1.16克，5.75毫摩尔)，滴加完之后反应混合物在0℃搅拌2小时，LCMS跟踪显示反应完成，减压浓缩除去四氢呋喃，残留物用1:1的乙酸乙酯和石油醚的混合液打浆，然后过滤除掉不溶物，收集到的滤液浓缩干后得到粗产品，粗品用快速柱层析(石油醚/乙酸乙酯梯℃5:1到1:1)纯化得到1.5克粗品化合物4-D。
步骤4：
把上述化合物4-D(1.5克)溶于30毫升二氯甲烷中，在0℃加入一水合肼(316.97毫克，5.38毫摩尔，85％纯度)，反应升温到9℃并搅拌16小时，薄层色谱(乙酸乙酯/石油醚＝1/1)跟踪显示反应结束，然后把不溶物过滤，收集到的滤液减压浓缩得到残留物，用柱层析(石油醚/乙酸乙酯溶液50％～100％)精制纯化得到化合物4-E(380毫克，两步收率42％)。
步骤5：
在14℃下，把化合物4-E(380毫克，1.64毫摩尔)溶于20毫升干燥的二氯甲烷中，随后依次分批加入EDCI(405.89毫克，2.12毫摩尔)，HOBt(286.10毫克，2.12毫摩尔)和二异丙基乙基胺(378.89毫克，2.93毫摩尔)，最后加入(2S,5R)-6-苄氧基-7-氧-1,6-二氮杂二环[3.2.1]辛-2-羧酸1-2(450毫克，2.63毫摩尔)，然后反应混合物在14℃搅拌2小时，LCMS跟踪显示反应完成，反应溶剂用减压浓缩除去，残留物用柱层析分离纯化(石油醚/乙酸乙酯＝3/1～1/1梯度洗脱)得到粗品，粗品用制备色谱进一步纯化得到化合物4-F(200毫克，收率25％)。
步骤6：
在14℃下把化合物4-F(200毫克，0.407毫摩尔)溶解在10毫升无水四氢呋喃中，然后氮气置换空气三次，加入10％的湿钯碳(150毫克)，然后氢气置换三次，反应混合物在氢气球下搅拌1.5小时，LCMS监测显示反应完全，用硅藻土过滤除去钯催化剂，滤液减压浓缩干得到160毫克粗品化合物4-G直接用于下一步反应。
步骤7：
在15℃左右把化合物4-G(160毫克)溶于水中，氮气保护下加入三甲胺三氧化硫络合物(55.61毫克，0.4毫摩尔)，最后加入三乙胺(8.09毫克，0.08毫摩尔)，反应混合液在15℃下搅拌16小时，LCMS显示反应完成，用10毫升饱和硫酸二氢钠淬灭反应并调节反应液pH到5左右，然后用乙酸乙酯/石油醚(1:1)的混合溶液洗涤2次，每次15毫升，再往水相中加入四丁基硫酸氢铵(271.33毫克，0.8毫摩尔)并在15℃搅拌10分钟，然后用乙酸乙酯萃取两次，每次25毫升，合并有机相，并用10毫升食盐水洗涤一次，无水硫酸钠干燥过滤浓缩得到化合物4-H(260毫克，收率90％)。
步骤8：
把化合物4-H(260毫克，0.36毫摩尔)溶于7毫升二氯甲烷中，然后冷却到0℃，缓慢加入三氟乙酸(1.08克，9.45毫摩尔)，反应混合物升温到15℃搅拌1小时，LCMS显示反应完全，反应溶剂在15℃浓 缩除去溶剂和大部分三氟乙酸，残留物用乙腈打浆三次，每次20毫升，得到化合物4(60毫克，收率43％)。1H NMR(400MHz,D2O)δ4.21-4.09(m,3H),4.08-3.92(m,5H),3.25(d,J＝11.6Hz,1H),3.06(d,J＝12.0Hz,1H),2.22-1.96(m,4H),1.94-1.68(m,2H).
实施例5:化合物5
Figure PCTCN2017087004-appb-000011
化合物5以1-叔丁氧羰基-3-吡咯烷酮(1-A)为起始原料，采用与实施例4相同的方法合成得到。1H NMR(400MHz,D2O)δ4.13(d,J＝2.0Hz,1H),4.06(t,J＝6.0Hz,2H),4.00(d,J＝6.6Hz,1H),3.43(dd,J＝5.0,10.0Hz,2H),3.34-3.21(m,2H),3.14(d,J＝12.6Hz,1H),3.06(d,J＝12.0Hz,1H),2.05(dd,J＝3.4,6.0Hz,6H),1.95-1.82(m,1H),1.81-1.70(m,1H)；
实施例6:化合物6
Figure PCTCN2017087004-appb-000012
化合物6以1-叔丁氧羰基-4-哌啶酮(3-A)为起始原料，采用与实施例4相同的方法合成得到。1H NMR(400MHz,D2O)δ4.18(br.s.,1H),4.13-4.00(m,3H),3.37-3.17(m,5H),3.14-3.07(m,1H),2.20-2.07(m,1H),1.97-1.73(m,9H).
实施例7:化合物7
Figure PCTCN2017087004-appb-000013
Figure PCTCN2017087004-appb-000014
步骤1：
在-20℃下往2-A(10克，58.41毫摩尔)四氢呋喃(30毫升)中缓慢滴加1摩尔/升的烯丙基溴化镁溶液(75.94毫升，75.94毫摩尔)，加完后，反应混合物在氮气保护下搅拌2小时，薄层色谱跟踪显示，反应完全，直接把反应液倒入饱和氯化铵溶液中淬灭反应，再用乙酸乙酯萃取3次，每次100毫升，合并萃取的有机相，用饱和食盐水洗涤3次，每次100毫升。然后用无水硫酸钠干燥有机相，布氏漏斗抽滤，减压浓缩得到粗产品，再用快速层析柱(石油醚/乙酸乙酯＝10/～5/1梯度洗脱)快速分离纯化得到14.5克粗品化合物7-B。1H NMR(400MHz,CDCl3)δ5.76-5.96(m,1H),5.13-5.36(m,2H),3.76-3.96(m,4H),2.63-2.78(m,1H),2.52(d,J＝7.20Hz,2H),1.45(s,9H)。
步骤2：
在0℃及氮气保护下往化合物7-B(3.00克，14.07毫摩尔)的四氢呋喃(100毫升)溶液中缓慢加入浓度为1摩尔/升的硼烷四氢呋喃溶液(28.14毫升，28.14毫摩尔)，然后反应温度缓慢升至20℃，搅拌1小时，薄层色谱分析表明原料7-B消耗完全，此时把反应重新冷却到0℃，缓慢加入3摩尔/升的氢氧化钠溶液9.38毫升，紧接着加入双氧水(3.19克，28.14毫摩尔，30％)，然后反应温度升至20℃并搅拌2小时，薄层色谱显示反应中间体消耗完全，把反应液倒入10毫升水中，用乙酸乙酯萃取三次，每次20毫升，合并的有机相用饱和食盐水洗涤2次，每次20毫升，再用无水硫酸钠干燥，布氏漏斗抽滤，减压浓缩得到粗品，粗品用柱层析精制得到化合物7-C(2.6克，收率80％)
步骤3：
在15℃下把化合物7-C(1.60克，6.92毫摩尔)和N-羟基邻苯二甲酰亚胺1-1(1.24克，7.61毫摩尔)溶 于四氢呋喃(15毫升)，氮气保护下加入三苯基膦(2.72克，10.38毫摩尔)，然后把反应加热到40℃左右，缓慢滴加偶氮二甲酸二异丙酯(2.10克，10.38毫摩尔，2.02毫升)，然后反应温度降到15℃继续搅拌1小时，薄层色谱跟踪显示原料7-C消耗完全，反应溶剂减压浓缩除去，残留物用层析柱(石油醚/乙酸乙酯＝10/1～1/1梯度洗脱)分离纯化得到化合物7-D(1.1克，收率42％)。
步骤4：
在15℃下把化合物7-D(1.1克，9.2毫摩尔)溶解在20毫升二氯甲烷中，再加入85％的一水合肼(0.36毫升，5.84毫摩尔)，反应混合液在15℃搅拌一小时，薄层色谱跟踪分析显示反应完全，反应中析出的固体过滤移除，滤液减压浓缩干，残留物用层析柱(15％的乙酸乙酯到100％的乙酸乙酯石油醚溶液梯度洗脱)分离纯化得到750毫克含有部分杂质的化合物7-E。
步骤5：
在0℃下，把化合物7-E(580毫克，2.35毫摩尔)溶于10毫升干燥的二氯甲烷中，随后依次分批加入(2S,5R)-6-苄氧基-7-氧-1,6-二氮杂二环[3.2.1]辛-2-羧酸1-2(650.62毫克，2.35毫摩尔)，EDCI(586.85毫克，3.06毫摩尔)，HOBt(413.64毫克，3.06毫摩尔)和二异丙基乙胺(456.51毫克，3.53毫摩尔)，然后反应混合物在15℃搅拌16小时，薄层色谱分析显示反应完成，反应溶剂用减压浓缩除去，残留物用柱层析分离纯化(石油醚/乙酸乙酯＝3/1～0/1梯度洗脱)得到化合物7-F(470毫克，收率37％)。
步骤6：
在15℃下，把化合物7-F(470毫克，0.93毫摩尔)溶于10毫升无水四氢呋喃，氮气保护下加入含量为10％的干钯碳100毫克，反应悬浮物用氢气置换三次，然后在氢气球氛围中搅拌18小时，薄层色谱分析显示反应进行完全，反应中的催化剂用硅藻土过滤，滤液减压浓缩得到400毫克粗品化合物7-G。
步骤7：
在15℃下，把上述化合物7-G(400毫克)溶解在20毫升水中，然后氮气保护下加入三甲胺三氧化硫络合物(134.32毫克，0.96毫摩尔)，反应混合物在15℃搅拌16小时，LCMS监测显示反应完全，反应溶液用15毫升饱和磷酸二氢钠溶液稀释，然后用2:1的石油醚/乙酸乙酯洗涤两次，每次30毫升，再往水相加入四丁基硫酸氢铵(491.54毫克，1.45毫摩尔)，用乙酸乙酯萃取2次，每次30毫升，合并有机相，用无水硫酸钠干燥，过滤浓缩得到化合物7-H(500毫克，收率70％)。
步骤8：
在0℃下，把化合物7-H(500毫克，0.68毫摩尔)溶于13毫升二氯甲烷中，再加入三氟乙酸(1.50毫升，20.26毫摩尔)，反应混合物在氮气保护下搅拌1小时，LCMS跟踪显示反应完成，反应溶剂和大部分三氟乙酸在0℃左右真空浓缩干，残余物用乙腈打浆三次，每次20毫升，收集到的固体然后溶于水，冻干得化合物7(170毫克，收率62％)。1H NMR(400MHz,D2O)δ4.15(br.s.,1H),4.08-3.86(m,7H),3.26(d,J＝12.0Hz,1H),3.07(d,J＝12.0Hz,1H),2.16-2.01(m,2H),1.95-1.84(m,3H),1.84-1.73(m,1H),1.68-1.66(m,2H)。
实施例8:化合物8
Figure PCTCN2017087004-appb-000015
化合物8以1-叔丁氧羰基-3-吡咯烷酮(1-A)为起始原料，采用与实施例7相同的方法合成得到。1H NMR(400MHz,D2O)δ4.13(d,J＝2.4Hz,1H),3.99(d,J＝6.8Hz,1H),3.91(t,J＝5.4Hz,2H),3.43(dd,J＝5.0,9.80Hz,2H),3.29-3.17(m,2H),3.08(m,2H),2.13-1.61(m,10H)。
实施例9:化合物9
Figure PCTCN2017087004-appb-000016
化合物9以1-叔丁氧羰基-4-哌啶酮(3-A)为起始原料出发，采用与实施例7相同的方法合成得到。1H NMR(400MHz,D2O)δ4.11(s,1H),3.98(d,J＝6.8Hz,1H),3.89-3.75(m,2H),3.25-3.13(m,5H),3.08(d,J＝12.0Hz,1H),2.06-1.98(m,2H),1.79-1.56(m,10H).
实验例1：体外协同抑制浓度(SIC)测试方法
协同抑制浓度测试的建立基于临床实验室标准化协会(CLSI)方法M7，联用的抗生素起始浓度为128微克/毫升，进行连续的稀释，总共是11个系列稀释浓度，活性的β-内酰胺酶抑制剂测试浓度固定在4微克/毫升。
实验目的：
本实验旨在评估实施例中的化合物在体外活性中对比参照化合物OP-0595是否具有优势，本系列实验从两个角度来考察：一方面是实施例中的化合物恢复抗生素的抗菌活性或者对抗生素产生增效作用；另一方面化合物自身相对于抗生素的抗菌能力。
实验方法：
1)待测化合物溶解(如果不溶解可以悬浮)在二甲基亚砜中稀释到浓度为12.8毫克/毫升作为原液，头孢他啶(CAZ)溶解在水中稀释到25.6毫克/毫升，厄它培南(ETP)溶解在磷酸缓冲溶液(PBS)中稀释到25.6毫克/毫升。
2)向96-V孔板的第2-12列内加入30微升二甲基亚砜。将60微升配制好的头孢他啶加到第1列内。从第1列取30微升头孢他啶到第2列，用排枪混匀。同样的操作直到第11列，将第11列的混合物弃去30微升。这是化合物母板。
3)将浓度为12.8毫克/毫升待测化合物的用DMSO稀释为0.8毫克/毫升后取30微升加入到母板的一列中。用排枪混匀母板内的液体。
4)在实验前一天，将保存在-80℃冰箱内的甘油菌取一环划线在胰酶大豆琼脂平板(TSA)上，将该平板放于37℃培养箱过夜培养。在实验当天，将细菌单克隆悬浮在生理盐水内并将浊度调为0.5标准麦氏浊 度，相当于1×108CFU/毫升。将此悬浮液用阳离子调节米勒-辛顿肉汤(CAMHB)稀释100倍至1×106CFU/毫升，此为接种液。。
5)96-U型板作为实验板。先往实验板的所有孔内加入98微升CAMHB.将母板内的溶液转移2微升到实验板内。取100微升接种液加到实验板的所有孔内。实验板的每一行包括头孢他啶/待测化合物或厄他培南/待测化合物的浓度分别为128/4,64/4,32/4,16/4,8/4,4/4,2/4,1/4,0.5/4,0.25/4,0.125/4,0/4微克/毫升。
6)实验板放在37℃培养20小时。头孢他啶的最低抑菌浓度为可以完全或明显抑制细菌生长的最低浓℃。
待测化合物或者抗生素单独的抗菌活性的测定同样采用上述的方法，表1是本实验所用的产β-内酰胺酶的细菌菌株的具体信息：
表1产β-内酰胺酶的细菌菌株的种类以及来源
Figure PCTCN2017087004-appb-000017
注1:表1中细菌菌株产β-内酰胺酶的种类来源于供应商的公开网络信息；
注2：“ATCC”是“American Type Culture Colletcion”的缩写，“CCUG”是“Culture Collection University of Goteborg”的缩写，“NCTC”是“NCTC–National Collection of Type Culture”的缩写。
实验结果：
见表2～4。
表2化合物1与头孢他啶的对细菌的协同抑制作用(单位：μg/mL)
Figure PCTCN2017087004-appb-000018
表3化合物1-H2与头孢他啶的对细菌的协同抑制作用(单位：μg/mL)
Figure PCTCN2017087004-appb-000019
表4化合物4与头孢他啶的对细菌的协同抑制作用(单位：μg/mL)
Figure PCTCN2017087004-appb-000020
结论：
化合物1恢复头孢他啶抗生素的抗菌活性的能力与参照化合物OP-0595完全相当，在ATCC BAA-1705和ATCC BAA-1143菌株中，活性提高4到8倍。综合来看，化合物1的体外活性表现要略优于参照化合物OP-0595，要显著优于REF-1。化合物1-H2恢复或者增效头孢他啶的能力与参照化合物OP-0595完全相当，特别是对两种克雷伯肺炎杆菌ATCC 51503和ATCC BAA-1898，化合物1-H2的增效作用要高8倍以上；另外，化合物1-H2本对阴沟肠科杆菌也表现出抑菌活性，抑菌浓度均在8微克/毫升以下，与OP-0595相当。因此，化合物1拆分后的异构体1-H2要优于参照化合物OP-0595。化合物4体外活性也要略优于参照化合物OP-0595。
实验例2：体外酶学实验方法
实验目的：
本试验旨在评估实施例中的化合物相比OP-0595对β-内酰胺酶的抑制活性的优势。
试验方法：
表5酶学实验100微升反应体系
Figure PCTCN2017087004-appb-000021
1)化合物溶于DMSO中制备储存母液(12.8毫克/毫升,按照实验例1的方法)；
2)制备缓冲溶液A(1×PBS,pH 7.4,0.1毫克/毫升BSA)供酶TEM-1和AmpC测试用；
3)在一96孔尖底板中，将化合物母液于DMSO中进行11次4倍的梯度稀释，此为工作液。使用96孔平底板为测试孔板，每孔中预先加入对应的反应缓冲液，随后每孔加相应体积的工作液(100μM-0.095nM和0nM)。其中，EDTA-Na2作为NDM-1测试的对照起始终浓度为20mM；
4)加入对应的β-内酰胺酶，将测试孔板于37℃孵育5分钟；
5)加入5μl Nitrocefin(终反应体积为100微升)；使用酶标仪对平板内反应溶液的吸光度OD490进行跟踪记录，每分钟读取一次吸光度，跟踪30分钟；
6)酶标仪可以给出OD490随时间增长的曲线。于曲线的线性范围内选取两个数据点Abs1和Abs2计算曲线斜率(Abs2-Abs1)/(T2-T1)。
7)相对抑制率的计算公式如下：Slope(EC)为在没有抑制剂时的斜率，Slop(S)为在某一抑制剂浓度时的斜率。
Figure PCTCN2017087004-appb-000022
相对抑制率和对应的抑制剂浓度用于计算该抑制剂对β-内酰胺酶的IC50值。本实验使用GraphPad Prism 5.0自带的公式，log(inhibitor)vs.normalized response—Variable slope,计算IC50。
备注：PBS指的是磷酸盐缓冲溶液；BSA指的是牛血清白蛋白
实验结果：见表6：
表6化合物对β-内酰胺酶抑制试验结果
Figure PCTCN2017087004-appb-000023
结论：
相比参照化合物OP-0595，化合物1和其拆分后的异构体1-H1和1-H2对β-内酰胺酶TEM-1和AmpC的IC50值要低4到53倍，表明三个化合物对β-内酰胺酶的抑制活性相比参照化合物OP-0595提高了4倍以上。可见，实施例中化合物1及其拆分的异构体1-H1和1-H2均要显著优于参照化合物OP-0595。
实验例3：小鼠大腿肌肉感染模型
实验目的：
本试验旨在考察实施例中的化合物在小鼠大腿肌肉感染模型中的是否具有药效，并进一步评估其药效对比参照化合物OP-0595是否具有显著优势。
实验材料：
7周左右大小的雌性CD-1小鼠，体重26～28克左右；环磷酰胺感染前4天注射150毫克/千克，1天前再注射100毫克/千克；感染细菌为阴沟肠杆菌1143(AmpC)。化合物1，1-H2，参照化合物OP-0595 均有实验室合成。
实验流程：
每只雌性CD-1小鼠通过右腿肌肉注射100微升菌液感染肺炎克雷伯细菌，感染剂量为每只小鼠大于5.00E+05CFU，感染后2小时，各组小鼠通过尾静脉给予相对应的化合物或者联用化合物治疗，第一次治疗间隔8小时后，给予第二轮治疗。
小鼠于感染后24小时安乐死，取右腿大腿肌肉置入盛有10毫升无菌生理盐水的50毫升离心管中，放在湿冰上转移至BSL-2实验室进行CFU计数。
肌肉组织使用IKA T10匀浆机研磨(最高转速20S，重复一次)，匀浆液梯度稀释后点于胰蛋白胨大豆琼脂平板，置入37℃培养箱进行细菌培养，24h后，取出平板，数出平板上各稀释梯度匀浆液长出的单菌落数，并由此计算每只小鼠右腿腿部肌肉的荷菌量。
实验方案：
表7化合物1和参照化合物OP-0595在小鼠大腿肌肉感染模型的药效评价方案
Figure PCTCN2017087004-appb-000024
表8化合物1-H2和参照化合物OP-0595在小鼠大腿肌肉感染模型的药效评价方案
Figure PCTCN2017087004-appb-000025
实验结果：
按照表7的实验方案，在抗生素头孢他啶(CAZ)/化合物1＝400/100mpk条件下，药效结果见图1和图2。
结论:
化合物1组比参照化合物OP-0595多降低了0.59log，其药效提高了3.9倍。化合物1药效明显优于参照化合物OP-0595。化合物1-H2相对于参考化合物OP-0595在该模型中的不同剂量下均显示出了更优的药效。
三个实验从不同的方面进行了评估，实施例中的化合物均表现出了相对于参照化合物OP-0595的明显优势。因此，在目前急需临床新药来对抗日益严重的耐药菌感染的情况下，实施例中的化合物是解决这一问题的一类极具潜力的可开发药物。可以预测，相比较目前一致看好的参照化合物OP-0595，实施例中的化合物可能会在未来的临床中显现出其更优的临床效果。

Claims (4)

  1. 式(I)所示化合物或其药学上可接受的盐，
    Figure PCTCN2017087004-appb-100001
    其中，
    m为1或2；
    n为1或2；
    i为1、2或3。
  2. 根据权利要求1所述化合物或其药学上可接受的盐，选自
    Figure PCTCN2017087004-appb-100002
  3. 一种药物组合物，其含有治疗有效量的根据权利要求1～2任意一项所述的化合物或其药学上可接受的盐和药学上可接受的载体。
  4. 根据权利要求1～2任意一项所述的化合物或其药学上可接受的盐或根据权利要求3所述的药物组合物在制备用于治疗细菌感染的β-内酰胺酶抑制剂中的应用。
PCT/CN2017/087004 2016-06-03 2017-06-02 新型二氮杂二环β-内酰胺酶抑制剂 Ceased WO2017206948A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610392575.1 2016-06-03
CN201610392575 2016-06-03

Publications (1)

Publication Number Publication Date
WO2017206948A1 true WO2017206948A1 (zh) 2017-12-07

Family

ID=60478028

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/087004 Ceased WO2017206948A1 (zh) 2016-06-03 2017-06-02 新型二氮杂二环β-内酰胺酶抑制剂

Country Status (1)

Country Link
WO (1) WO2017206948A1 (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014091268A1 (en) * 2012-12-11 2014-06-19 Naeja Pharmaceutical Inc. NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
US20140288051A1 (en) * 2011-12-02 2014-09-25 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
CN104768951A (zh) * 2012-08-25 2015-07-08 沃克哈特有限公司 1,6-二氮杂双环[3,2,1]辛-7-酮衍生物及其在治疗细菌感染中的用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140288051A1 (en) * 2011-12-02 2014-09-25 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
CN104768951A (zh) * 2012-08-25 2015-07-08 沃克哈特有限公司 1,6-二氮杂双环[3,2,1]辛-7-酮衍生物及其在治疗细菌感染中的用途
WO2014091268A1 (en) * 2012-12-11 2014-06-19 Naeja Pharmaceutical Inc. NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS

Similar Documents

Publication Publication Date Title
US11433053B2 (en) LSD1 inhibitor and preparation method and application thereof
US11040968B2 (en) Pyridine derivative as ASK1 inhibitor and preparation method and use thereof
US11117899B2 (en) [1,2,4]triazolo[1,5-c]pyrimidine derivative as A2A receptor inhibitor
JP6838773B2 (ja) 抗インフルエンザウイルスのピリミジニル誘導体
JP2019529386A5 (zh)
RU2741963C2 (ru) НОВЫЕ ИНГИБИТОРЫ β-ЛАКТАМАЗ
US10981900B2 (en) Spiro compound and use thereof
CA3054324C (en) Tri-cycle compound and applications thereof
CA2951971C (en) PYRIDINO ANALOGUE [1,2-A] PYRIMIDONE USED AS A PI3K INHIBITOR
US11312715B2 (en) Fused ring derivative as A2A receptor inhibitor
AU2016248886B2 (en) Pyridopyrimidinones and their use as NMDA receptor modulators
TW200925158A (en) Carbacephem β-lactam antibiotics
JP2023544653A (ja) 複素環置換の縮合γ－カルボリン誘導体、その製造方法、中間体及び使用
CN107614498B (zh) 二氮杂-苯并荧蒽类化合物
WO2017206948A1 (zh) 新型二氮杂二环β-内酰胺酶抑制剂
US20180104220A1 (en) Imidazole compound
US20250195699A1 (en) Radiolabeled Mu Opioid Antagonist and Methods of Making and Using the Same
HK40000487A (zh) 新型β-内酰胺酶抑制剂
HK40000487B (zh) 新型β-内酰胺酶抑制剂
US20190202838A1 (en) Anti-hcmv virus compound
BR112019004420B1 (pt) Composição farmacêutica
BR112020006185B1 (pt) Compostos ou sais farmaceuticamente aceitáveis dos mesmos e uso dos mesmos
BR112019014152B1 (pt) Compostos inibidores seletivos de hdac6, composição farmacêutica compreendendo os referidos compostos e uso dos mesmos

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17805893

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17805893

Country of ref document: EP

Kind code of ref document: A1